Remember what happened the last time physician groups opposed federal efforts to curtail Medicare spending on Part B drugs?
The Community Oncology Alliance filed a lawsuit against the White House Office of Management and Budget and HHS on May 30 to reverse the application of the federal budget sequester to Medicare reimbursement for Part B drugs.
The complaint, filed in federal court for the District of Columbia, caps a long-running effort by the organization to return...
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
